Olysio

  • Email
  • Help

Questions & Answers

On 20 March 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Olysio, 150 mg, hard capsules intended for the treatment of chronic hepatitis C (CHC). The applicant for this medicinal product is Janssen-Cilag International N.V. They may request a re-examination of any CHMP opinion, provided they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion.

The active substance of Olysio is simeprevir, antivirals for systemic use (J05AE) and a specific inhibitor of the HCV NS3/4A serine protease.

The benefits with Olysio are its efficacy demonstrated in the treatment of chronic hepatitis C in adult patients when used in combination with other medicinal products. The most common side effects (incidence ≥ 5%) are were nausea, rash, pruritus, dyspnoea, blood bilirubin increase and photosensitivity reaction.

A pharmacovigilance plan for Olysio will be implemented as part of the marketing authorisation.

The approved indication is: "OLYSIO is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients (see sections 4.2, 4.4 and 5.1). For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.". It is proposed that Olysio be prescribed by physicians experienced in the treatment of chronic hepatitis C (CHC).

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CHMP, on the basis of quality, safety and efficacy data submitted, considers there to be a favourable benefit-to-risk balance for Olysio and therefore recommends the granting of the marketing authorisation.

Name Language First published Last updated
CHMP summary of positive opinion for Olysio (English only) 21/03/2014  

Key facts

Product details for Olysio
NameOlysio
INN or common name

simeprevir

Therapeutic area Hepatitis C, Chronic
Active substance

simeprevir

Date opinion adopted20/03/2014
Company name

Janssen-Cilag International N.V.

StatusPositive
Application typeInitial authorisation